Skip to main content
. 2013 Feb 19;108(5):1052–1060. doi: 10.1038/bjc.2013.69

Table 2. Correlation between baseline characteristics and VEGF-A and VEGFR-2 concentrations (all arms pooled).

 
VEGF-A
VEGFR-2
  Low, n (%) (n=197) High, n (%) (n=196) Interaction P-value Low, n (%) (n=197) High, n (%) (n=196) Interaction P-value
Age, years
<65 157 (80) 156 (80) 1.0000 149 (76) 164 (84) 0.0599
⩾65
40 (20)
40 (20)
 
48 (24)
32 (16)
 
ECOG PS
0 125 (63) 120 (61) 0.6739 118 (60) 127 (65) 0.4616
1 68 (35) 74 (38)   74 (38) 68 (35)  
2
1 (<1)
0
 
1 (<1)
0
 
Disease-free interval
⩽median 67 (34) 70 (36) 0.8320 70 (36) 67 (34) 0.9156
>median
128 (65)
125 (64)
 
127 (64)
126 (64)
 
ER status
Negative 49 (25) 54 (28) 0.5662 56 (28) 47 (24) 0.3604
Positive
148 (75)
140 (71)
 
141 (72)
147 (75)
 
ER/PgR combined
Negative 40 (20) 40 (20) 1.0000 48 (24) 32 (16) 0.0600
Positive
157 (80)
155 (79)
 
149 (76)
163 (83)
 
No. of metastatic sites
⩾3 87 (44) 95 (48) 0.5425 94 (48) 88 (45) 0.6119
<3 106 (54) 101 (52)   101 (51) 106 (54)  

Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; ER=oestrogen receptor; PgR=progesterone receptor; VEGF-A=vascular endothelial growth factor A; VEGFR-2=vascular endothelial growth factor receptor 2.